托法替布联合DMARDs方案用于类风湿性关节炎的效果及安全性评价  

Efficacy and Safety Evaluation of Tofacitinib Combined with DMARDs in Rheumatoid Arthritis

作　　者：黄辉[1] 黄艳[1] 杨丹丹 李晓英 黄俊俏 黄丽娜 HUANG Hui;HUANG Yan;YANG Dandan;LI Xiaoying;HUANG Junqiao;HUANG Lina(Department of Rheumatology and Immunology,Baise People′s Hospital,Baise 533000,Guangxi Zhuang Autonomous Region,China)

机构地区：[1]百色市人民医院风湿免疫科,广西百色533000

出　　处：《系统医学》2025年第1期1-3,12,共4页Systems Medicine

基　　金：白求恩·医学科学研究基金资助项目合同书(TY065DS);百色市科学研究与技术开发计划课题(20204741)。

摘　　要：目的探讨托法替布联合缓解疾病进展的抗风湿药(disease-modifying anti-rheumatic drugs,DMARDs)用于类风湿关节炎(rheumatoid arthritis,RA)的效果及安全性评价。方法非随机选取2021年4月—2022年3月百色市人民医院风湿免疫科收治的198例RA患者为研究对象。并根据治疗方案不同分为两组,每组99例。对照组采用DMARDs方案用药治疗,研究组采用DMARDs联合托法替布用药治疗,治疗时间均为8周。对比两组疗效、不良反应、关节功能情况。结果研究组治疗总有效率为94.95%(94/99),高于对照组的82.83%(82/99),差异有统计学意义(χ^(2)=7.364,P<0.05)。两组不良反应发生率对比,差异无统计学意义(P>0.05)。治疗后研究组关节肿胀评分及关节压痛评分均低于对照组,差异有统计学意义(P均<0.05)。结论RA患者应用DMARDs方案联合托法替布疗效高于单一DMARDs方案,且症状改善更明显。Objective To evaluate the efficacy and safety of tofacitinib combined with disease-modifying anti rheumatic drugs(DMARDs)for rheumatoid arthritis(RA).Methods A total of 198 RA patients admitted to the Depart⁃ment of Rheumatology and Immunology of Baise People′s Hospital from April 2021 to March 2022 were non randomly selected as the research objects.They were divided into two groups according to different treatment plans,with 99 cases in each group.The control group was treated with DMARDs regimen,while the study group was treated with DMARDs combined with Tofacitinib.The treatment time of the two groups was 8 weeks.The efficacy,adverse re⁃actions and joint function of the two groups were compared.Results The total effective rate of the study group was 94.95%(94/99),which was higher than 82.83%(82/99)of the control group,the difference was statistically significant(χ^(2)=7.363,P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the joint swelling score and joint tenderness score of the study group were lower than those of the control group,and the differences were statistically significant(both P<0.05).Conclusion The effect of DMARDs combined with tofacitinib in RA patients was higher than that of DMARDs alone,and the improvement of symptoms was more obvious.

关 键 词：托法替布 类风湿性关节炎 疗效 抗风湿药 不良反应 

分 类 号：R4[医药卫生—临床医学]